These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 11061655

  • 1. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.
    Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, Brundage RC, Remmel RP.
    AIDS; 2000 Sep 29; 14(14):2137-44. PubMed ID: 11061655
    [Abstract] [Full Text] [Related]

  • 2. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.
    Anderson PL, Kakuda TN, Kawle S, Fletcher CV.
    AIDS; 2003 Oct 17; 17(15):2159-68. PubMed ID: 14523272
    [Abstract] [Full Text] [Related]

  • 3. Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.
    Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, Long MC, Kuritzkes DR, Sommadossi JP.
    Antivir Ther; 2007 Oct 17; 12(6):981-6. PubMed ID: 17926654
    [Abstract] [Full Text] [Related]

  • 4. Development of a pharmacodynamic model for HIV treatment with nucleoside reverse transcriptase and protease inhibitors.
    Hurwitz SJ, Schinazi RF.
    Antiviral Res; 2002 Nov 17; 56(2):115-27. PubMed ID: 12367718
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetic Modeling of Lamivudine and Zidovudine Triphosphates Predicts Differential Pharmacokinetics in Seminal Mononuclear Cells and Peripheral Blood Mononuclear Cells.
    Dumond JB, Yang KH, Kendrick R, Reddy YS, Kashuba AD, Troiani L, Bridges AS, Fiscus SA, Forrest A, Cohen MS.
    Antimicrob Agents Chemother; 2015 Oct 17; 59(10):6395-401. PubMed ID: 26239974
    [Abstract] [Full Text] [Related]

  • 6. Abacavir-lamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: A randomized equivalence trial.
    Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V, Hicks C, Hammer SM, Cooper D, Johnson M, Tortell S, Cutrell A, Thorborn D, Isaacs R, Hetherington S, Steel H, Spreen W, CNAAB3005 International Study Team.
    JAMA; 2001 Mar 07; 285(9):1155-63. PubMed ID: 11231744
    [Abstract] [Full Text] [Related]

  • 7. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
    Eron JJ, Yetzer ES, Ruane PJ, Becker S, Sawyer GA, Fisher RL, Tolson JM, Shaefer MS.
    AIDS; 2000 Apr 14; 14(6):671-81. PubMed ID: 10807190
    [Abstract] [Full Text] [Related]

  • 8. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
    Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.
    AIDS; 2000 Jul 28; 14(11):1591-600. PubMed ID: 10983646
    [Abstract] [Full Text] [Related]

  • 9. Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.
    Goodgame JC, Pottage JC, Jablonowski H, Hardy WD, Stein A, Fischl M, Morrow P, Feinberg J, Brothers CH, Vafidis I, Nacci P, Yeo J, Pedneault L.
    Antivir Ther; 2000 Sep 28; 5(3):215-25. PubMed ID: 11075942
    [Abstract] [Full Text] [Related]

  • 10. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection.
    Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, Brundage RC.
    AIDS; 2002 Mar 08; 16(4):551-60. PubMed ID: 11872998
    [Abstract] [Full Text] [Related]

  • 11. Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults.
    Anderson PL, Zheng JH, King T, Bushman LR, Predhomme J, Meditz A, Gerber J, Fletcher CV.
    AIDS; 2007 Sep 12; 21(14):1849-54. PubMed ID: 17721092
    [Abstract] [Full Text] [Related]

  • 12. A randomized, open-label, comparative trial of zidovudine plus lamivudine versus zidovudine plus lamivudine plus didanosine in antiretroviral-naive HIV-1-infected Thai patients.
    Ungsedhapand C, Kroon ED, Suwanagool S, Ruxrungtham K, Yimsuan N, Sonjai A, Ubolyam S, Buranapraditkun S, Tiengrim S, Pakker N, Kunanusont C, Lange JM, Cooper DA, Phanuphak P.
    J Acquir Immune Defic Syndr; 2001 Jun 01; 27(2):116-23. PubMed ID: 11404532
    [Abstract] [Full Text] [Related]

  • 13. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320.
    Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM.
    Ann Intern Med; 2001 Dec 04; 135(11):954-64. PubMed ID: 11730396
    [Abstract] [Full Text] [Related]

  • 14. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group.
    Katlama C, Ingrand D, Loveday C, Clumeck N, Mallolas J, Staszewski S, Johnson M, Hill AM, Pearce G, McDade H.
    JAMA; 1996 Jul 10; 276(2):118-25. PubMed ID: 8656503
    [Abstract] [Full Text] [Related]

  • 16. Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
    Phillips AN, Eron J, Bartlett J, Kuritzkes DR, Johnson VA, Gilbert C, Johnson J, Keller A, Hill AM.
    AIDS; 1997 Feb 10; 11(2):169-75. PubMed ID: 9030363
    [Abstract] [Full Text] [Related]

  • 17. Simultaneous quantitation of intracellular zidovudine and lamivudine triphosphates in human immunodeficiency virus-infected individuals.
    Rodriguez JF, Rodriguez JL, Santana J, García H, Rosario O.
    Antimicrob Agents Chemother; 2000 Nov 10; 44(11):3097-100. PubMed ID: 11036029
    [Abstract] [Full Text] [Related]

  • 18. An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.
    Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, Jurriaans S, Roos MT, Vandermeulen K, de Wolf F, Lange JM.
    AIDS; 1998 Aug 20; 12(12):1513-9. PubMed ID: 9727573
    [Abstract] [Full Text] [Related]

  • 19. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
    Ruane PJ, Parenti DM, Margolis DM, Shepp DH, Babinchak TJ, Van Kempen AS, Kauf TL, Danehower SA, Yau L, Hessenthaler SM, Goodwin D, Hernandez JE, COL30336 Study Team.
    HIV Clin Trials; 2003 Aug 20; 4(4):231-43. PubMed ID: 12916008
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of purified recombinant reverse transcriptase from wild-type and zidovudine-resistant clinical isolates of human immunodeficiency virus type 1 by zidovudine, stavudine, and lamivudine triphosphates.
    Duan C, Poticha D, Stoeckli TC, Petropoulos CJ, Whitcomb JM, McHenry CS, Kuritzkes DR.
    J Infect Dis; 2001 Nov 15; 184(10):1336-40. PubMed ID: 11679926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.